Article Text

Download PDFPDF
Palivizumab for children with Down syndrome: is the time right for a universal recommendation?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors BP drafted the letter, and SM reviewed the letter and revised the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests BP has received an investigator-initiated research grant from AbbVie Corporation and compensation as an advisor and speaker for AbbVie. SM has no conflicts to declare.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Correction notice This article has been amended slightly since it was published Online First. In the first paragraph ‘due to several dysmorphic features’ has been changed to ‘as a result of structural variants’.

  • Patient consent for publication Not required

Linked Articles